These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25648339)

  • 21. Electrocardiographic Abnormalities, Malignant Ventricular Arrhythmias, and Cardiomyopathy Associated With Loperamide Abuse.
    Vaughn P; Solik MM; Bagga S; Padanilam BJ
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1230-1233. PubMed ID: 27461785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early afterdepolarizations, U waves, and torsades de pointes.
    Wu J; Wu J; Zipes DP
    Circulation; 2002 Feb; 105(6):675-6. PubMed ID: 11839619
    [No Abstract]   [Full Text] [Related]  

  • 23. A case of short-coupled variant of torsade de pointes characterized by spatial heterogeneity of action potential duration and its restitution kinetics.
    Yamazaki M; Osaka T; Yokoyama E; Kodama I
    J Interv Card Electrophysiol; 2006 Oct; 17(1):35-40. PubMed ID: 17253122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiarrhythmic and cardiac electrophysiological effects of SZV-270, a novel compound with combined Class I/B and Class III effects, in rabbits and dogs.
    Varga RS; Hornyik T; Husti Z; Kohajda Z; Krajsovszky G; Nagy N; Jost N; Virág L; Tálosi L; Mátyus P; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2021 Jan; 99(1):89-101. PubMed ID: 32970956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings.
    Locati EH; Maison-Blanche P; Dejode P; Cauchemez B; Coumel P
    J Am Coll Cardiol; 1995 Jun; 25(7):1564-75. PubMed ID: 7539014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs.
    Motokawa Y; Nakamura Y; Hagiwara-Nagasawa M; Goto A; Chiba K; Lubna NJ; Izumi-Nakaseko H; Ando K; Naito AT; Yamazaki H; Sugiyama A
    Cardiovasc Toxicol; 2018 Jun; 18(3):242-251. PubMed ID: 29139031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
    Grouthier V; Lebrun-Vignes B; Glazer AM; Touraine P; Funck-Brentano C; Pariente A; Courtillot C; Bachelot A; Roden DM; Moslehi JJ; Salem JE
    Heart; 2018 Nov; 104(22):1859-1863. PubMed ID: 29720397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detailed analysis of 24 hour ambulatory electrocardiographic recordings during ventricular fibrillation or torsade de pointes.
    Lewis BH; Antman EM; Graboys TB
    J Am Coll Cardiol; 1983 Sep; 2(3):426-36. PubMed ID: 6192159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stormy petrel. Polymorphic ventricular tachycardia.
    Martinez-Lopez JI
    J La State Med Soc; 1994 Apr; 146(4):111-4. PubMed ID: 8006493
    [No Abstract]   [Full Text] [Related]  

  • 30. [Definition of ventricular tachycardia].
    Coumel P
    Arch Mal Coeur Vaiss; 1993 May; 86(5 Suppl):701-4. PubMed ID: 8267496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-terminating ventricular tachyarrhythmias--a diagnostic dilemma?
    Clayton RH; Murray A; Higham PD; Campbell RW
    Lancet; 1993 Jan; 341(8837):93-5. PubMed ID: 8093413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative contributions of TRIaD and QT to proarrhythmia.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):655-7. PubMed ID: 17488264
    [No Abstract]   [Full Text] [Related]  

  • 33. [Torsades de pointes].
    Guize L; Iliou MC; Bayet G; Lavergne T; Le Heuzey JY
    Arch Mal Coeur Vaiss; 1993 May; 86(5 Suppl):769-76. PubMed ID: 8267505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revised definition of M cell and torsade de pointes in long QT syndrome.
    Takahashi N
    J Cardiovasc Electrophysiol; 2005 Sep; 16(9):988-90. PubMed ID: 16174021
    [No Abstract]   [Full Text] [Related]  

  • 35. Old habits die hard: the quest for correct(ed) QT interval measurements.
    Husser D; Hindricks G
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):914-5. PubMed ID: 20626523
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypothyroidism and congenital long QT: additive effect causing torsades?
    Elsheshtawy M; Yang F; Khanna A
    Europace; 2018 Apr; 20(4):635. PubMed ID: 29016752
    [No Abstract]   [Full Text] [Related]  

  • 37. Ventricular fibrillation and torsades de pointes.
    Dessertenne F; Coumel P; Fabiato A
    Cardiovasc Drugs Ther; 1990 Aug; 4(4):1177-82. PubMed ID: 2083198
    [No Abstract]   [Full Text] [Related]  

  • 38. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia.
    Abe K; Takada K; Yoshiya I
    Anesth Analg; 1998 Apr; 86(4):701-2. PubMed ID: 9539586
    [No Abstract]   [Full Text] [Related]  

  • 39. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
    Bertino JS; Owens RC; Carnes TD; Iannini PB
    Clin Infect Dis; 2002 Mar; 34(6):861-3. PubMed ID: 11830802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.